Pyelonephritis News and Research

RSS

Pyelonephritis is an ascending urinary tract infection that has reached the ''pyelum'' (pelvis) of the kidney (''nephros'' in Greek).

Does your diet increase the risk of recurring urinary tract infections?

The influence of behavioral risk factors such as diet, body weight, and lifestyle on the prevalence of urinary infections.

6 Feb 2024

Study finds new drug combination to be more effective against complicated urinary tract infections

An international study led by a Rutgers scientist comparing new and older treatments against complicated urinary tract infections has found a new drug combination to be more effective, especially against stubborn, drug-resistant infections.

25 Oct 2022

Study finds reductions in hospital admissions for childhood infections during first year of pandemic

During the first year or so of the covid-19 pandemic, there were dramatic reductions in hospital admissions for common and severe childhood infections in England, most likely due to social distancing measures, school and workplace closures, and travel restrictions, finds a study published by The BMJ today.

13 Jan 2022

Forgotten antibiotic may be useful in treating severe febrile urinary tract infections

A forgotten antibiotic, temocillin, led to lower selection of resistant bacteria than the standard treatment for febrile urinary tract infection, in a study published in The Lancet Infectious Diseases.

29 Oct 2021

Lund researchers discover how E. coli bacteria target and degrade MYC oncogene

Scientists at Lund University have discovered how E. coli bacteria target and degrade the well-known oncogene MYC, which is involved in many forms of cancer.

13 Feb 2021

Going vegan lowers risk of urinary tract infection

Urinary tract infections (UTIs) are usually caused by bacteria, such as Escherichia coli, which is normally found in the gut but enters the urinary tract through the urethra. UTIs, when left untreated, can reach and affect the kidneys. It is one of the most common microbial infections across the globe, with a worldwide prevalence of 10 in 1,000 people.

30 Jan 2020

Acute kidney injury on the rise in hospitalized pregnant women

A study presented at ASN Kidney Week 2019 (November 5 to November 10) shows that the rate of acute kidney injury (AKI) is rising among US women who are hospitalized in pregnancy. The highest risk is in pregnant diabetic women. Women who suffer acute damage to the kidney while pregnant have 260 times the risk of death while in hospital compared to other pregnant women, at 2.6% vs 0.01%. Both mother and baby are at risk of increased illness and death if the woman has kidney injury during pregnancy.

11 Nov 2019

Kazan University researchers study the genetics of nephropathia epidemica

This particular inquiry pertains to CCR5 - a gene which has lately been on the focuses of research worldwide. In particular, CCR5 deletion was used in China to perform the first ever genetic editing on human embryos. It's also known that a CCR5-Δ32 mutation can make people immune to HIV.

10 Oct 2019

NHS England pilot paves way for new smartphone-based UTI test

WOMEN who suspect they have a urinary tract infection will be able to access fast-track testing and treatment — without seeing a GP — as part of a ground-breaking NHS England pilot scheme being trialed in 38 ‘Pharmacy First’ branches across Nottinghamshire and Derbyshire.

19 Jul 2019

Antibiotic susceptibility pattern of Enterobacteriaceae found in Ghana

Passing on dangerous naked explosives: the state of multiple antibiotic resistant Enterobacteriaceae in Cape Coast, Ghana.

29 Jun 2019

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Alnylam announces positive results from Phase 1/2 study of lumasiran for treating primary hyperoxaluria-1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today updated positive results from its Phase 1/2 clinical study of lumasiran, an investigational, subcutaneously administered RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1.

4 Oct 2018

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.

24 Sep 2018

Alnylam announces new positive results from Phase 1/2 study of lumasiran in patients with PH1

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, announced today new positive results from its Phase 1/2 study with lumasiran, an investigational RNAi therapeutic targeting glycolate oxidase for the treatment of Primary Hyperoxaluria Type 1.

8 Jun 2018

New drug treatment linked to higher bladder compliance after spinal cord injury

Researchers have shown that compared to placebo, a drug treatment intended to prevent remodeling of the bladder wall and given within 48 hours after spinal cord injury (SCI) in dogs was associated with significantly higher bladder compliance.

7 Sep 2017

FDA approves new antibacterial treatment for adults with cUTI

The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits certain types of resistance mechanisms used by bacteria.

30 Aug 2017

New study shows how increase in medication-resistant bacteria impedes treatment of kidney infections

The increase in illnesses and deaths linked to medication-resistant bacteria has been well-documented by researchers and received extensive public attention in recent years. Now, UCLA-led research shows how these bacteria are making it more difficult to treat a common but severe kidney infection.

16 Sep 2016

Switch to rituximab shows anti-inflammatory effect in relapsing-remitting MS

Rituximab may be an attractive treatment option for patients with relapsing-remitting multiple sclerosis, suggest phase II study findings showing its efficacy in controlling inflammatory activity.

22 Jun 2016

New therapeutic target to treat bacterial infections may substitute antibiotics

Infections continue to threaten human health. With remarkable genetic flexibility, pathogenic organisms outsmart available therapies. Fortunately, microbial versatility is matched by the host immune system, which evolves in dialogue with the microbes. Therapies that enhance the beneficial effects of the immune response represent a promising, but under-explored, therapeutic alternative to antibiotics.

29 Apr 2016

Pooled analysis from seven clinical studies demonstrates consistent efficacy for ceftazidime-avibactam in the treatment of multi-drug resistant gram-negative bacteria

AstraZeneca has presented positive data demonstrating the efficacy of the investigational antibiotic, ceftazidime-avibactam (CAZ-AVI), in treating patients with ceftazidime-resistant Gram-negative infections, which are increasingly resistant to most available antibiotics, often precipitating the need for clinicians to reach for agents previously reserved for last-line use.

12 Apr 2016